Abstract
A number of biomarkers have been identified for various cancers. However, biomarkers associated with glioma remain largely to be explored. In the current study, we investigated the relationship between the expression and prognostic value of the HIST1H2BK gene in glioma. Sequential data filtering (survival analysis, independent prognostic analysis, ROC curve analysis, and clinical correlation analysis) was performed, which resulted in identification of the association between the HIST1H2BK gene and glioma. Then, the HIST1H2BK gene was analyzed using bioinformatics (Kaplan–Meier survival analysis, univariate Cox analysis, multivariate Cox analysis, and ROC curve analysis). The results showed that low expression of HIST1H2BK was associated with better prognosis, and high expression of HIST1H2BK was associated with poor prognosis. In addition, HIST1H2BK was an independent prognostic indicator for patients with glioma. We also evaluated the association between HIST1H2BK and clinical characteristics. Furthermore, gene set enrichment analysis (GSEA) and analysis of immune infiltration were performed. The results showed that HIST1H2BK was associated with intensity of immune infiltration in glioma. Finally, co-expression analysis was performed. The results showed that HIST1H2BK was positively correlated with HIST1H2AG, HIST2H2AA4, HIST1H2BJ, HIST2H2BE, and HIST1H2AC, and negatively correlated with PDZD4, CRY2, GABBR1, rp5-1119a7.17, and KCNJ11. This study showed that upregulation of HIST1H2BK in low-grade glioma (LGG) tissue was an indicator of poor prognosis. Moreover, this study demonstrated that HIST1H2BK may be a promising biomarker for the treatment of LGG.
Highlights
Glioma is one of the most common primary intracranial malignancies, and it encompasses two principle subgroups: diffuse gliomas and gliomas showing a more circumscribed growth pattern (“non-diffuse gliomas”) [1, 2]
This study investigated the relationship between HIST1H2BK and glioma prognosis
HIST1H2BK was analyzed for correlations with prognosis and clinical characteristics
Summary
Glioma is one of the most common primary intracranial malignancies, and it encompasses two principle subgroups: diffuse gliomas and gliomas showing a more circumscribed growth pattern (“non-diffuse gliomas”) [1, 2]. The prognosis of glioma is still poor due to the infiltrative nature of this malignancy, and a high local relapse rate [6]. Zeng et al suggested that TRPM8 may be a promising biomarker of GBM invasiveness, and a potential target for treatment of glioblastoma [12]. In the future, these markers may be used for advanced diagnostic and decision-making processes. These markers may be used for advanced diagnostic and decision-making processes Despite these advances, more reliable prognostic indicators are needed for glioma [13]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
